Ardelyx (ARDX)
NASDAQ:ARDX
Want to see ARDX full AI Analyst Report?
Top Page
Ardelyx
(NASDAQ:ARDX)
Select Model
Select Model
Rating:59Neutral
Price Target:
$7.00
▲(8.53% Upside)
Action:ReiteratedDate:05/02/26
The score is held back most by weak financial quality (ongoing losses, negative free cash flow, and higher leverage). Offsetting this are strong technical momentum and a constructive earnings update with reiterated high-growth revenue guidance, while valuation remains constrained by negative earnings.
Positive Factors
Revenue growth & high gross margins
Ardelyx has sustained strong product revenue acceleration alongside very high gross margins, indicating product-level economics that support scalable profitability as volumes grow. Durable margin strength gives pricing and reinvestment flexibility while management scales commercialization.
Negative Factors
Rising leverage
Leverage has increased materially while the company remains loss‑making, raising refinancing and covenant risks. Elevated debt reduces financial flexibility, increases fixed costs, and makes funding future R&D or commercialization more contingent on capital markets or operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & high gross margins
Ardelyx has sustained strong product revenue acceleration alongside very high gross margins, indicating product-level economics that support scalable profitability as volumes grow. Durable margin strength gives pricing and reinvestment flexibility while management scales commercialization.
Read all positive factors
Ardelyx (ARDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.69B
Dividend YieldN/A
Average Volume (3M)3.12M
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth18.24%
EPS Growth-5.21%
CountryUS
Employees395
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding245,247,420
10 Day Avg. Volume2,765,699
30 Day Avg. Volume3,116,047
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue4.60
Enterprise Value/Gross Profit5.00
Enterprise Value/Ebitda-57.78
Forecast
1Y Price Target
$16.60Price Target Upside157.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$549.70M
Ardelyx Business Overview & Revenue Model
Company Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, ...
How the Company Makes Money
Ardelyx makes money primarily through (1) product sales from its commercial medicines and (2) collaboration-related payments (when applicable), such as license revenue, milestone payments, and royalties from partners. Product revenue is generated ...
Ardelyx Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call presented multiple strong operational and commercial achievements — notably robust Ibsrela growth (58% YoY), solid product revenue expansion (+38% total product revenue), active pipeline advancement (EXCEL Phase 3 initiated with rapid site activation), improved net loss versus prior year, and strengthened financial optionality via debt refinancing and $238M in cash. Headwinds include elevated and growing OpEx tied to commercialization and Phase 3 activity, GAAP reporting complexity for Exposa due to prior‑year adjustments, Q1 seasonality and storm‑related disruptions, and near‑term gross‑to‑net pressure. On balance the company reiterated mid‑ and long‑term revenue targets and appears confident in execution, though profitability and competitive risk remain items to monitor.Positive Updates
Strong Q1 Revenue Growth
Total product revenues of $93.4M in Q1 2026, up 38% year-over-year from $67.8M, driven primarily by Ibsrela demand.
Negative Updates
Elevated Operating Expenses and Planned OpEx Ramp
SG&A rose to $102.3M in Q1 2026 from $83.2M in Q1 2025 (≈+23%), R&D increased to $20.2M from $14.9M (≈+36%) driven by EXCEL; company guidance anticipates ~ $520M total OpEx for 2026 and ~25% operational expense growth, putting pressure on near‑term profitability.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Revenue Growth
Total product revenues of $93.4M in Q1 2026, up 38% year-over-year from $67.8M, driven primarily by Ibsrela demand.
Read all positive updates
Company Guidance
Ardelyx reiterated 2026 product revenue guidance of $520–$550 million (Ibsrela $410–$430M, +50–57% YoY; Exposa $110–$120M), implying full‑year product revenue growth of 38–46% while operational expenses are expected to grow ~25% with OpEx guidance of about $520M; management expects quarter‑over‑quarter demand increases, a 2029 Ibsrela target of at least $1.0 billion (≈38% CAGR), and reported Q1 product revenues of $93.4M (+38% YoY) including Ibsrela $70.1M (+58% YoY) and Exposa $23.3M (paid prescriptions +19% YoY; Exposa expenses +32%); Q1 R&D was $20.2M (vs $14.9M), SG&A $102.3M (vs $83.2M), net loss $37.6M or $0.15/sh (vs $41.1M, $0.17), share‑based comp $14.2M, cash and short‑term investments $238.1M, debt facility $300M ($200M drawn, $100M available), and gross‑to‑net ~36.4% in Q1 (blended low‑30s for FY); specialty pharmacy programs drove higher fulfillment and roughly one additional refill per patient on average.Ardelyx Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
43
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 427.68M | 407.32M | 333.62M | 124.46M | 52.16M | 10.10M |
| Gross Profit | 393.18M | 364.72M | 283.06M | 106.66M | 48.04M | 9.10M |
| EBITDA | -34.05M | -37.92M | -16.71M | -55.35M | -60.98M | -150.85M |
| Net Income | -58.06M | -61.60M | -39.14M | -66.07M | -67.21M | -158.16M |
Balance Sheet | ||||||
| Total Assets | 504.51M | 501.60M | 435.75M | 297.58M | 190.07M | 149.91M |
| Cash, Cash Equivalents and Short-Term Investments | 238.07M | 264.69M | 250.10M | 184.30M | 123.91M | 116.69M |
| Total Debt | 208.26M | 211.59M | 153.44M | 55.98M | 36.46M | 45.50M |
| Total Liabilities | 355.88M | 334.65M | 262.46M | 130.76M | 91.74M | 67.30M |
| Stockholders Equity | 148.62M | 166.95M | 173.29M | 166.82M | 98.33M | 82.62M |
Cash Flow | ||||||
| Free Cash Flow | -37.50M | -43.98M | -45.82M | -90.06M | -70.10M | -154.42M |
| Operating Cash Flow | -36.26M | -42.48M | -44.81M | -89.72M | -70.04M | -152.55M |
| Investing Cash Flow | -21.80M | -8.96M | -18.32M | -131.25M | 18.41M | 50.95M |
| Financing Cash Flow | 58.47M | 54.51M | 106.59M | 146.29M | 75.34M | 83.00M |
Ardelyx Technical Analysis
Positive
6.45
Price Trends
6.21
Positive
6.35
Positive
5.89
Positive
Market Momentum
0.08
Negative
61.67
Neutral
77.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDX, the sentiment is Positive. The current price of 6.45 is above the 20-day moving average (MA) of 5.92, above the 50-day MA of 6.21, and above the 200-day MA of 5.89, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 61.67 is Neutral, neither overbought nor oversold. The STOCH value of 77.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARDX.
Ardelyx Risk Analysis
Ardelyx disclosed 52 risk factors in its most recent earnings report. Ardelyx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ardelyx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.81B | 110.29 | 5.17% | ― | 16.45% | 57.39% | |
66 Neutral | $4.76B | -9.59 | ― | ― | -67.35% | -58.36% | |
61 Neutral | $3.28B | -12.72 | -31.97% | ― | ― | -12.95% | |
59 Neutral | $1.69B | -9.79 | -40.63% | ― | 18.24% | -5.21% | |
57 Neutral | $1.89B | -7.95 | -70.76% | ― | ― | -25.27% | |
54 Neutral | $1.37B | -5.48 | -58.44% | ― | 23359.93% | -0.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ARDX
Ardelyx
7.30
3.57
95.45%
VCEL
Vericel
36.49
-2.77
-7.06%
VRDN
Viridian Therapeutics
14.06
0.94
7.16%
DNTH
Dianthus Therapeutics
89.34
67.79
314.57%
PHVS
Pharvaris
30.02
11.36
60.88%
EWTX
Edgewise Therapeutics
31.45
14.91
90.15%
Ardelyx Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Ardelyx Posts Strong Q1 2026 Revenue, Reaffirms Guidance
Positive
Apr 30, 2026
On April 30, 2026, Ardelyx reported first quarter 2026 product revenue of $93.4 million, up 38% year over year, driven by strong adoption of IBSRELA and XPHOZAH. IBSRELA revenue rose 58% to $70.1 million and XPHOZAH contributed $23.3 million, whil...
Business Operations and StrategyFinancial Disclosures
Ardelyx Posts Strong 2025 Results, Projects 2026 Growth
Positive
Feb 19, 2026
On February 19, 2026, Ardelyx reported its fourth-quarter and full-year 2025 results, highlighting a 73% surge in IBSRELA revenue to $274.2 million and total revenue of $407.3 million, alongside $103.6 million from XPHOZAH. Despite higher RD and S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.